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Abstract
Background: Metabolic syndrome (MetS) has been related to type 2 diabetes and cardiovascular diseases.
Different criteria for diagnosis of MetS have been recommended, but there is no agreement about which criteria
are best to use. The aim of the present study was to investigate agreement between the National Heart, Lung, and
Blood Institute, American Heart Association (NHLBI/AHA) and the International Diabetes Federation (IDF) definitions
of MetS in patients with symptomatic carotid disease and to compare the frequency of cardiovascular risk factor in
patients with MetS diagnosed by these two sets of criteria.
Methods: The study was a cross-sectional one involving 644 consecutive patients with verified carotid disease who
referred to the Vascular Surgery Clinic Dedinje in Belgrade during the period April 2006 - November 2007.
Anthropometric parameters blood pressure, fasting plasma glucose and lipoproteins were measured using standard
procedures.
Results: MetS was present in 67.9% of participants, according to IDF criteria, and in 64.9% of participants,
according to the NHLBI/AHA criteria. A total of 119 patients were categorized differently by the two definitions.
Out of all participants 10.7% had MetS by IDF criteria only and 7.8% of patients had MetS by NHLBI/AHA criteria
only. The overall agreement of IDF and NHLBI/AHA criteria was 81.5% (Kappa 0.59, p < 0.001). In comparison with
patients who met only IDF criteria, patients who met only NHLBI/AHA criteria had significantly more frequently
cardiovascular risk factors with the exception of obesity which was significantly more frequent in patients with
MetS diagnosed by IDF criteria.
Conclusion: The MetS prevalence in patients with symptomatic carotid disease was high regardless of criteria used
for its diagnosis. Since some patients with known cardiovascular risk factors were lost by the use of IDF criteria it
seems that NHLBI/AHA definition is more suitable for diagnosis of MetS. Large follow-up studies are needed to test
prognostic value of these definitions.
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Background
During the last two decades metabolic syndrome (MetS)
has become one of the major public-health challenges
worldwide [1]. In 1988 Reaven was first to describe Syn-
drome X, and defined it as a cluster of hypertension,
glucose intolerance, elevated tryglycerides and low level
of high density lipoprotein (HDL) cholesterol [2].
Ferrannini et al. suggested that this clustering was
caused by insulin resistance and called it insulin resis-
tance syndrome [3]. World Health Organization (WHO)
defined the syndrome and changed its name to meta-
bolic syndrome [4]. In 2001 the National Cholesterol
Education Program - Adult treatment Panel III (NCEP-
ATP III) proposed both diagnostic criteria for metabolic
syndrome and cut-off points for its components
(abdominal obesity, hypertension, increased level of tri-
glycerides and fasting plasma glucose and low level of
HDL- C) [5]. NCEP-ATP III criteria were revised in
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National Heart, Lung, and Blood Institute (NHLBI) -
modified NCEP-ATP III criteria, called also NHLBI-
AHA criteria [6], and in 2006 International Diabetes
Federation recommended a new definition of metabolic
syndrome - IDF definition [7].
According to the literature data, the prevalence of
MetS depends on the definition used [8-11]. The con-
cordance between various definitions has most fre-
quently been high [9,10], although there are some
subjects in whom MetS was diagnosed by one definition
only and not by other(s). There is no agreement about
which criteria for MetS diagnose are best to use.
The aim of the present study was to investigate agree-
ment between the NHLBI/AHA and the IDF definitions
of MetS in patients with symptomatic carotid disease
and to compare the frequency of cardiovascular risk fac-
tor in patients with MetS diagnosed by these two sets of
criteria.
Methods
The study used for the present investigation was cross-
sectional. It involved consecutive patients with verified
carotid disease who referred to the Vascular Surgery
Clinic Dedinje in Belgrade during the period April 2006
- November 2007. In the study were included 644 sub-
jects who had symptoms of cerebral ischemia and caro-
tid stenosis of ≥ 5 0 % ,a c c o r d i n gt oN A S C E Tc r i t e r i a
[12]. Carotid atherosclerosis was estimated by high reso-
lution B-mode ultrasonography.
Patients under eighteen years of age, with malignant
disease, previous endarectomy or rheumatoid arthritis,
were excluded.
For all participants anthropometric parameters and
data on cardiovascular risk factors were collected.
Waist circumference was measured at the midway
between lower rib and crista iliaca according to WHO
recommendations [13].
Body weight was assessed by using a calibrated stan-
dard balance-beam, height was measured by a standard
height bar, and Body Mass Index (BMI) was calculated
as weight (kg) divided by height (m
2) [13]. Percent of
body fat was assessed according to the method proposed
by Durnin and Womerslaj [14].
Blood pressure was measured using the method
recommended by the Seventh Report of the Joint
National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure [15].
For estimation of metabolic parameters, fasting plasma
glucose (FPG) and lipoproteins, blood samples were
obtained after an overnight fast and avoidance of liquids.
Levels of fasting plasma glucose (FPG), total cholesterol
(TC), serum triglycerides (TG), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol
(LDL-C) and serum uric acid level were estimated using
commercial kits (Abbot, IL, USA) on an automated ana-
lyzer (AEROSET™, Abbot, IL, USA). Levels of high sen-
sitivity C-reactive protein (hsCRP) and fibrinogen were
measured by using Immunoturbidimetric fixed time test
(Olympus Diagnostics, O’Callaghan’s Mills Co. Clare,
Ireland).
According to NHLBI/AHA criteria [6] metabolic syn-
drome was diagnosed when three or more of the follow-
ing risk factors were present: abdominal obesity (> 102
cm in men, and > 88 cm in women), hypertension ≥
130/≥ 85 mmHg or specific medication, level of trigly-
cerides ≥ 150 mg/dl (1.7 mmol/L) or specific medica-
tion, low HDL cholesterol: in men < 40 mg/dl (1.03
mmol/L), and in women < 50 mg/dl (1.29 mmol/L) or
specific medication, and fasting plasma glucose ≥ 100
mg/dl (5.6 mmol/L) or history of diabetes mellitus or
taking antidiabetic medications.
According to the IDF criteria MetS include abdominal
obesity (> 94 cm in men, and > 80 cm in women), plus
any two of the same risk factors as in NHLBI/AHA cri-
teria: hypertension ≥ 130/≥ 85 mmHg or antihyperten-
sive therapy, level of triglycerides ≥ 150 mg/dl (1.7
mmol/L) or specific medication, low HDL cholesterol: in
men < 40 mg/dl (1.03 mmol/L), and in women < 50
mg/dl (1.29 mmol/L) or specific medication, and fasting
plasma glucose ≥ 100 mg/dl (5.6 mmol/L) or history of
diabetes mellitus or taking antidiabetic medications.
Statistical analysis
Categorical variables were presented by counts and per-
centages. Continuous variables were described as means
with 95% confidence interval. Kappa statistics was used
to measure agreement between the two criteria.
ANOVA was applied for mutual comparisons of cardio-
vascular risk factors in subjects with MetS according to
IDF, NHLBI/AHA and both criteria and subjects with-
out MetS, as well as for comparison of cardiovascular
risk factors among gender. Data were analyzed using
SPSS package version 15 with significance level set to
0.05.
The study was reviewed and given ethical approval by
the Ethics Committee at the Faculty of Medicine in Bel-
grade. All patients gave written, informed consent.
Results
The study included 644 patients with symptomatic caro-
tid disease, 402 (62.4%) males and 242 (37.6%) females
(Table 1).
Of 644 patients, 437 (67.9%) had metabolic syndrome
according to IDF criteria and 418 (64.9%) according to
the NHLBI/AHA criteria. The prevalence of metabolic
syndrome was 60.9% in males and 79.3% in females
according to the IDF criteria, and 61.4% in males and
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A total of 119 patients were categorized differently by
the two definitions. Out of all participants 69 (10.7%)
had MetS only by IDF criteria (42 males and 27
females), and 50 (7.8%) patients had MetS only by
NHLBI/AHA criteria.
The overall agreement of IDF and NHLBI/AHA cri-
teria was 81.5% (Kappa 0.59, p < 0.001). There were sig-
nificant differences in agreement between the two
metabolic syndrome definitions based on sex and age. In
males agreement was 78.6% (Kappa 0.55, p < 0.001) and
in females 86.4% (Kappa 0.64 p < 0.001). For age groups
agreement ranged from 69.2% (Kappa = 0.36, p < 0.001),
for subjects 35-54 years old, to 88.2% (Kappa = 0.72, p
< 0.001), for subjects 65-69 years old.”
Comparisons of cardiovascular risk factors in patients
with metabolic syndrome diagnosed by IDF and NHLBI/
AHA criteria, and in patients without metabolic syn-
drome, are presented in Table 2 and Table 3.
According to data presented in Tables 2 and 3, the
greatest differences in cardiovascular risk factors were
found between patients with MetS diagnosed by both
criteria and patients without MetS. Patients with MetS
were significantly more obese (BMI, WC and % of body
fat) and had significantly higher mean values of sistolic
and diastolic blood pressure, triglycerides, fasting blood
glucose and serum uric acid and significantly lower
mean value of HDL - C. In comparison with patients
without MetS, patients in whom MetS was diagnosed
only by IDF criteria had significantly higher mean values
of BMI and % of body fat and lower values of HDL-C.
Comparing with patients without MetS, those in whom
MetS was diagnosed only by NHLBI/AHA criteria had
significantly higher mean values of systolic blood pres-
sure, triglycerides and fasting plasma glucose, and lower
values of HDL-C. Significant differences in cardiovascu-
lar risk factors were found between patients with MetS
diagnosed by only one of the two criteria and patients
with MetS diagnosed by both criteria. In comparison
with patients in whom MetS was diagnosed by both cri-
teria, patients who met only IDF criteria were signifi-
cantly less obese (lower mean values of BMI, WC and %
body fat), had significantly lower mean levels of trigly-
cerides, glucose and serum uric acid and higher mean
level of HDL - C, while subjects who met only NHLBI/
AHA criteria were only significantly less obese (lower
mean levels of BMI, WC and % of body fat). In compar-
ison with patients who met only NHLBI/AHA criteria,
patients who met only criteria for IDF definition were
significantly more obese (higher values of BMI, WC and
% of body fat), but they had significantly lower mean
level of glucose and higher mean level of HDL - C.
Patients who met only NHLBI/AHA criteria had sig-
nificantly more frequently hypertension, elevated trigly-
ceride and glucose level and a low HDL-C level in
comparison with patients who met only IDF criteria
(Table 4).
Analyses of drug treatment in patients (antihyperten-
sive, hipolipidemic and for diabetes mellitus type 2) did
not change differences in observed cardiovascular risk
factors between compared groups (data not shown).
Discussion
In the present study metabolic syndrome prevalence in
patients with symptomatic carotid disease was high
regardless of criteria used for its diagnosis. According to
IDF criteria MetS had 67.9% of patients, and according
to the NHLBI/AHA criteria 64.9% of patients. The two
definitions were concordant in 81.5% of patients (Kappa
0.59, p < 0.001). In comparison with patients who met
only IDF criteria, patients who met only NHLBI/AHA
criteria had significantly more frequently cardiovascular
risk factors with the exception of obesity which was sig-
nificantly more frequent in patients with MetS diag-
nosed by IDF criteria.
Table 1 Frequency of metabolic syndrome by IDF and NHLBI/AHA criteria
Without MetS MetS by both criteria MetS by IDF only MetS by NHLBI/AHA only Chi square (p value)
a
Number (%) Number (%) Number (%) Number (%)
All participants (n = 644) 157 (24.4) 368 (57.1) 69 (10.7) 50 (7.8)
Gender:
Male (n = 402) 113 (28.1) 203 (50.5) 42 (10.4) 44 (10.9)
Female (n = 242) 44 (18.2) 165 (68.2) 27 (11.2) 6 (2.5) 28.39 (< 0.001)
Age group:
35-54 (n = 78) 20 (25.6) 34 (43.6) 13 (16.7) 11 (14.1)
55-64 (n = 199) 42 (21.1) 123 (61.8) 23 (11.6) 11 (5.5)
65-69 (n = 144) 34 (23.6) 93 (64.6) 11 (7.6) 6 (4.2)
70-74 (n = 142) 32 (22.5) 82 (57.7) 12 (8.5) 16 (11.3)
≥ 75 (n = 81) 29 (35.8) 36 (44.4) 10 (12.3) 6 (7.4) 27.29 (0.007)
a Chi-square tests was performed to assess variations in the distribution of patients among the four metabolic syndrome categories by sex and age.
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expected since it is known that the MetS prevalence is
high in population with verified atherosclerotic disease.
For example, according to Gorter et al. study [16], the
prevalence of MetS in various types of atherosclerotic
disease was in range from 41% in patients with coronary
heart disease, up to 58% in patients with peripheral
arterial disease.
The high agreement of two definitions is also not sur-
prising taking into account the fact that these definitions
had the same five components and that four of these
components are defined identically. IDF and NHLBI/
AHA, vary in two important aspects. First, in the IDF
criteria cut-off values for waist circumfernece are lower
than in modified NCEP criteria (NHLBI/AHA), and the
second and crucial, abdominal obesity is required as a
prerequisite for diagnosis of MetS.
Similar results were found in other studies. The
majority of these studies were performed in the samples
of total populations and only few of them in patients
with clinical atherosclerotic disease. In Li et al. study
[10] the prevalence of MetS by NHLBI/AHA definition
Table 2 Mean values of cardiovascular risk factors in patients with metabolic syndrome according to IDF and NHLBI/
AHA criteria and in patients without metabolic syndrome
Without MetS MetS by both criteria MetS by IDF only MetS by NHLBI/AHA only
(n = 157) (n = 368) (n = 69) (n = 50)
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI)
Age (years) 65.7 (64.4, 67.1) 65.3 (64.5, 66.0) 63.7 (61.5, 65.9) 64.9 (62.5, 67.4)
Body mass index (kg/m
2) 24.4 (23.9, 25.0) 29.0 (26.8, 27.4) 25.8 (25.3, 26.3) 23.4 (22.8, 24.1)
Waist circumference (cm) 89.9 (88.2, 91.7) 102.6 (101.7, 103.6) 92.0 (90.3, 93.6) 87.2 (85.6, 88.9)
% of body fat 27.7 (26.6, 28.7) 34.2 (33.6, 34.9) 30.8 (29.3, 32.2) 26.8 (25.4, 28.2)
Systolic blood pressure (mmHg) 138.1 (134.8, 141.2) 144.3 (142.4, 146.2) 141.9 (137.1, 146.7) 147.1 (141.2, 153.0)
Diastolic blood pressure (mmHg) 80.4 (78.6, 82.1) 84.1 (83.0, 85.0) 82.0 (79.2, 84.9) 81.7 (79.0, 84.3)
Triglycerides (mmol/L) 1.3 (1.2, 1.3) 2.2 (2.1, 2.3) 1.5 (1.4, 1.6) 1.9 (1.7, 2.1)
Total cholesterol (mmol/L) 5.2 (5.0, 5.4) 5.3 (5.2, 5.4) 5.1 (4.8, 5.3) 5.3 (4.9, 5.6)
HDL - C (mmol/L) 1.2 (1.1, 1.3) 1.0 (1.0, 1.0) 1.1 (1.0, 1.6) 0.9 (0.9, 1.0)
LDL - C (mmol/L) 3.5 (3.3, 3.6) 3.4 (3.3, 3.5) 3.2 (3.0, 3.5) 3.4 (3.1, 3.8)
Fasting plasma glucose (mmol/L) 4.8 (4.6, 4.9) 5.8 (5.6, 6.0) 5.0 (4.8, 5.2) 6.1 (5.4, 6.7)
hsCRP (mg/L) 4.7 (3.5, 5.9) 4.0 (3.4, 4.6) 3.9 (2.6, 5.3) 2.6 (1.7, 3.6)
Fibrinogen (g/L) 3.4 (3.3, 3.6) 3.4 (3.3, 3.5) 3.4 (3.1, 3.7) 3.2 (2.9, 3.5)
Serum uric acid (μmol/L) 315.2 (302.8, 327.6) 356.3 (346.6, 366.1) 325.0 (307.1, 342.9) 326.9 (302.0, 351.9)
HDL - C: High density lipoprotein cholesterol; LDL - C: Low density lipoprotein cholesterol; hsCRP: high sensitivity C reactive protein.
Table 3 Significant
a differences in cardiovascular risk factors in subjects with metabolic syndrome according to IDF,




















Body mass index (kg/m
2) < 0.001 < 0.001 < 0.001 0.043 0.001 -
Waist circumference (cm) < 0.001 < 0.001 < 0.001 - 0.034 -
% of body fat < 0.001 < 0.001 < 0.001 0.003 0.004 -
Systolic blood pressure
(mmHg)
0.006 - - - - 0.003
Diastolic blood pressure
(mmHg)
0.001 - - - - -
Triglycerides (mmol/L) < 0.001 < 0.001 - - - 0.001
HDL-C (mmol/L) < 0.001 0.037 - 0.029 0.015 < 0.001
Fasting plasma glucose
(mmol/L)
< 0.001 0.001 - - 0.002 < 0.001
Serum uric acid (μmol/L) < 0.001 0.045 - - - -
a p value according to ANOVA; HDL - C: High density lipoprotein cholesterol
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was 94.4% in men and 97.0% in women. According to
Athryos et al. [9] cross-sectional analysis of representa-
tive sample of Greek adults, the prevalence of MetS was
22.6% by NHLBI/AHA and 18.3% by IDF criteria. In a
cross-sectional study among Malays in Kuala Lumpur,
the MetS was diagnosed in 41.4% and 38.2% participants
using the NHLBI/AHA and the IDF criteria respectively
[11]. The use of the IDF MetS definition in the popula-
tion of the United States [17], led to a higher prevalence
estimate of the MetS than the use of NHLBI/AHA defi-
nition, although the two definitions similarly classified
~93% of the participants as having or not having the
MetS. Out of four MetS definition (WHO, EGIR,
NHLBI/AHA and IDF), applied in a population-based
cross- sectional study in four population of the Asia-
Pacific region [18], the highest prevalence of MetS was
obtained with the IDF definition. Hildrum et al. [8]
found that the prevalence of IDF-defined MetS was
29.6%, compared to 25.9% when using the NHLBI/AHA
criteria. In a case-control study in which the association
of first-ever acute ischemic non-embolic stroke with the
MetS was investigated, the prevalence of MetS in the
patients group was 57.1% by NHLBI/AHA and 69.9% by
IDF criteria and 18.1% and 30.7% in the control group
respectively. Among women with coronary artery dis-
ease, the prevalence of MetS was 70% and 74% by
NHLBI/AHA and IDF criteria [19]. In all these studies
differences in the prevalence of the MetS by two defini-
tions were present, but they were not significant and
not in the same direction. Yet, in some smaller or
greater number of subjects, the MetS was diagnosed by
only one of the two definitions.
What seems to be more important than the percen-
tage of MetS diagnosed by one or the other definition,
is which one of the two definitions better identifies sub-
jects at high risk of cardiovascular diseases. According
to Athryos et al. study [9], cardiovascular disease (CVD)
prevalence was increased in the presence of MetS irre-
spective of the definition used, but this increase was
more pronounced when NHLBI/AHA criteria were
applied in comparison with IDF definition. NHLBI/AHA
criteria were also better, in comparison with IDF cri-
teria, in identifying the metabolically abnormal, but
non-obese, groups known to be predisposed to type 2
diabetes and cardiovascular diseases [20]. Li et al. [10]
found that in the patients with hypertension, the IDF
defined MetS was more strongly associated with coron-
ary heart disease than NHLBI/AHA defined MetS, but it
was weakly or not associated with stroke. Milionis et al.
[21] reported that the implementation of the IDF MetS
definition, although substantially increased the number
of elderly subjects labeled as having MetS, did not con-
tribute to the identification of those at high risk of
stroke. Comparing prognostic utility of the two defini-
tions of MetS in postmenopausal women with angio-
graphic coronary heart disease, Brown et al. [19] stated
that their analysis suggested that both MetS definitions
successfully identified a subset of women at high risk
for future cardiovascular events. However, the number
of patients differentially classified by the two definitions
was small and there were few cardiovascular events
overall, so that they were unable to draw firm conclu-
sions about differences in the clinical characteristics or
risk for cardiovascular clinical outcomes between these
two definitions.
Table 4 Frequency of metabolic syndrome components in patients with metabolic syndrome according to IDF and
NHLBI/AHA criteria











IDF 62 (39.5) 368 (100.0) 69 (100.0) 0 (0.0)
NHLBI/AHA 35 (22.3) 297 (80.7) 0 (0.0) 0 (0.0)
Triglycerides
c 10 (6.4) 248 (67.4) 17 (24.6) 30 (60.0) < 0.001
Fasting plasma glucose
d 19 (12.1) 209 (56.8) 9 (13.0) 35 (70.0) < 0.001
Hypertension
e 110 (70.1) 351 (95.4) 60 (86.9) 49 (98.0) 0.032
HDL - C
f 60 (38.2) 320 (49.7) 52 (75.4) 49 (98.0) 0.001
a For comparison between IDF criteria only and NHLBI/AHA criteria only; p values were not calculated for waist circumference because of the basic differences
between the two metabolic syndrome definitions.
b > 94 cm in men and > 80 cm in women, by IDF criteria; > 102 cm in men and > 88 cm in women, by NHLBI/AHA criteria.
c ≥ 1.7 mmol/L or specific medication
d ≥ 5.6 mmol/L or history of diabetes mellitus or taking antidiabetic medication.
e Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or antihypertensive therapy.
f High density lipoprotein cholesterol < 1.03 mmol/L in men, and < 1.29 mmol/L in women or specific medication.
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pants so we cannot be sure about prognostic value of
any of the two definitions. However, cardiovascular risk
factors were more frequently present or were more
adverse in patients with MetS who met only NHLBI/
AHA criteria than in those who met only IDF criteria.
Patients who met only NHLBI/AHA criteria differ less
from patients whose MetS was diagnosed by both defini-
tions than patients who met only IDF criteria. Since
some patients with known cardiovascular risk factors
were lost by the use of IDF definition it seems that
NHLBI/AHA definition is more suitable for diagnosis of
MetS. Similar to our findings, in the cross-sectional
study in Malay cohort, Moy and Bulgiba [11] found that
blood pressure, glucose, total cholesterol and triglycer-
ides were more adverse in participants diagnosed by
NHLBI/AHA criteria than in the IDF group. They con-
cluded that their results suggested that central obesity
should not be the prerequisite for the development of
increased cardiometabolic risks and that for diagnosis of
MetS was better to use NHLBI/AHA than IDF criteria,
at least in their own population.
The main limitation of this study is its cross-sectional
design. Prospective studies are needed to find out which
of the two definitions, IDF or NHLBI/AHA, better
determines adverse events associated with the MetS.
Conclusion
The MetS prevalence in patients with symptomatic car-
otid disease was high regardless of criteria used for its
diagnosis. The two definitions were concordant in 81.5%
of patients, but since some patients with known cardio-
vascular risk factors were lost by the use of IDF defini-
tion, it seems that NHLBI/AHA definition is more
suitable for diagnosis of MetS. Large follow-up studies
are needed to test prognostic value of these definitions.
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